TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial
Go back to TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial| TG THERAP (NASDAQ: TGTX) | Delayed: 55.37 -0.61 (1.09%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $55.98 | 52 Week High | $14.87 | |||
| Open | $55.34 | 52 Week Low | $4.90 | |||
| Day High | $55.72 | P/E | N/A | |||
| Day Low | $54.09 | EPS | $-0.67 | |||
| Volume | 364,181 | |||||
